8-K: Klotho Neurosciences Faces Further Nasdaq Listing Deficiency Amidst Compliance Efforts

Klotho Neurosciences receives another notice from Nasdaq regarding non-compliance with listing rules, adding complexity to its ongoing efforts to regain compliance.

Summary

• Klotho Neurosciences received a delinquency notification from Nasdaq on August 16, 2024, for not meeting the minimum Market Value of Publicly Held Shares (MVPHS) and Market Value of Listed Securities (MVLS) requirements.
• The company requested a hearing before a Nasdaq Hearings Panel on February 21, 2025, which stayed any suspension or delisting action.
• At the hearing on March 27, 2025, Klotho Neurosciences presented a compliance plan to the Panel.
• On March 31, 2025, Nasdaq granted the company an extension until August 13, 2025, to regain compliance with the Bid Price Rule, contingent on achieving scheduled milestones.
• The company received another notice on October 15, 2024, for not maintaining a minimum bid price of $1 per share for its common stock over 30 consecutive business days.
• On April 15, 2025, Klotho Neurosciences received a notice from Nasdaq stating that it has not regained compliance with the Bid Price Rule.
• The Panel will consider this matter in their decision regarding the company's continued listing on Nasdaq, and the company must present its views in writing by April 22, 2025.
• Klotho Neurosciences believes its compliance plan demonstrates its ability to be in full compliance with Nasdaq Listing Rules by August 3, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the continued listing deficiencies and the uncertainty surrounding the company's ability to regain compliance. While an extension was granted, the additional notice and the need to present further views to the Panel indicate ongoing challenges.

Positives

• The company has been granted an extension to regain compliance with the Bid Price Rule until August 13, 2025.
• Klotho Neurosciences believes its compliance plan demonstrates its ability to be in full compliance with Nasdaq Listing Rules by August 3, 2025.

Negatives

• Klotho Neurosciences has received multiple delinquency notifications from Nasdaq for failing to meet minimum MVPHS, MVLS, and bid price requirements.
• The company has not regained compliance with the Bid Price Rule as of April 15, 2025.
• The Nasdaq Hearings Panel will consider the additional deficiency in their decision regarding the company's continued listing.

Risks

• Failure to meet the conditions of the extension granted by Nasdaq could lead to delisting.
• The Nasdaq Hearings Panel may not be satisfied with the company's compliance plan or its ability to regain compliance.
• Continued non-compliance with Nasdaq listing rules could negatively impact investor confidence and the company's stock price.

Future Outlook

Klotho Neurosciences aims to achieve full compliance with Nasdaq Listing Rules by August 3, 2025, and is actively working to address the deficiencies identified by Nasdaq.

Management Comments

• The Company believes that the Compliance Plan presented to the Panel at the Hearing demonstrates the Company's ability to be in full compliance with the Nasdaq Listing Rules by August 3, 2025.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum share price and market capitalization requirements. This situation highlights the importance of effective capital management and achieving key milestones to maintain investor confidence.

Comparison to Industry Standards

• Other biotech companies facing similar listing challenges often implement strategies such as reverse stock splits, securing additional funding, or demonstrating significant clinical progress to boost share value.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have faced scrutiny regarding their clinical trial data and regulatory pathways, impacting their stock performance and Nasdaq compliance.
• Compared to industry benchmarks, Klotho's situation is not unique, but the company's ability to execute its compliance plan and achieve key milestones will be critical for its continued listing.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty regarding the company's future.
• The company's ability to raise capital and pursue its business strategy could be affected.

Next Steps

• Klotho Neurosciences must present its views to the Nasdaq Hearings Panel by April 22, 2025.
• The company needs to execute its compliance plan to meet the conditions of the extension granted by Nasdaq.
• The Nasdaq Hearings Panel will make a decision regarding the company's continued listing on Nasdaq.

Key Dates

Keywords

Nasdaq, delisting, compliance, listing rules, MVPHS, MVLS, bid price, Klotho Neurosciences